financetom
Business
financetom
/
Business
/
Floor & Decor Well-Positioned for Long-Term Growth but Tariffs, Potential Recession May Limit Current Prospects, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Floor & Decor Well-Positioned for Long-Term Growth but Tariffs, Potential Recession May Limit Current Prospects, Morgan Stanley Says
May 26, 2025 12:38 AM

03:44 PM EDT, 05/02/2025 (MT Newswires) -- Tariffs eventually could position Floor & Decor Holdings ( FND ) favorably over the long term, although the home-improvement retailer also faces many uncertainties, including the broader economy and the relative health of the housing market on its performance, analysts at Morgan Stanley said on Friday in a new research note.

Overall, the Morgan Stanley analysts said they view Floor & Decor ( FND ) favorably, particularly for investors with a longer-term outlook. The company appears to be largely managing its various challenges well with a long runway of unit, revenue and earnings growth ahead, they said, but also cautioning those prospects are "highly levered to the macro environment."

At current levels, Floor & Decor ( FND ) share price is "demanding," with a price-to-earnings ratio of around 40 times its projected 2025 earnings range of $1.70 to $2.00 per share, the Morgan Stanley analysts said.

The analysts trimmed their price target for Floor & Decor ( FND ) shares to $105 from $115 per share previously, with the new price target reflecting a multiple of 38 times Morgan Stanley's projected 2026 earnings of $2.75 per share. The new forecast also factors in the growing risk of a recession and the analysts' expectations for same-store sales remaining flat coupled with gross margin expansion and sales, general and administrative deleveraging of 40 and 50 basis points, respectively.

The Morgan Stanley analysts on Friday also reiterated their equal-weight rating for Floor & Decor's ( FND ) stock, explaining the company's short-term risks and rewards are relatively balanced at this time.

Floor & Decor ( FND ) shares recently were nearly 3% in afternoon trading on Friday.

Price: 75.00, Change: +2.75, Percent Change: +3.80

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US dependence on Canada's oil should deter Trump tariffs, industry says
US dependence on Canada's oil should deter Trump tariffs, industry says
Nov 12, 2024
* Most of Canada's 4 million bpd of oil exports to go U.S. * U.S. cannot easily replace Canadian barrels * Stronger U.S. dollar could benefit Canadian producers, says analyst By Nia Williams Nov 12 (Reuters) - Canada's energy industry does not expect U.S. President-elect Donald Trump's broad plans for protectionist trade measures will include tariffs on Canadian oil imports,...
Oncolytics Biotech Q3 Loss Narrows
Oncolytics Biotech Q3 Loss Narrows
Nov 12, 2024
07:31 AM EST, 11/12/2024 (MT Newswires) -- Oncolytics Biotech ( ONCY ) on Tuesday reported a narrower loss for the third quarter. The net loss narrowed slightly to $9.5 million or $0.12 per share, from $9.9 million, or $0.14 per share, last year. The company, which booked no revenue for the quarter, reported a cash position of $19.6 million as...
Neumora Therapeutics Q3 Loss Narrows
Neumora Therapeutics Q3 Loss Narrows
Nov 12, 2024
07:31 AM EST, 11/12/2024 (MT Newswires) -- Neumora Therapeutics ( NMRA ) reported a Q3 loss Tuesday of $0.45 per diluted share, narrower than the loss of $1.14 a year earlier. Analysts polled by Capital IQ expected a loss of $0.39. The clinical-stage biopharmaceutical company did not report any revenue for the quarter ended Sept. 30. Neumora said it had...
Nuvalent's Q3 Net Loss Widens
Nuvalent's Q3 Net Loss Widens
Nov 12, 2024
06:53 AM EST, 11/12/2024 (MT Newswires) -- Nuvalent ( NUVL ) reported a Q3 net loss Tuesday of $1.28 per diluted share, widening from a loss of $0.59 a year earlier. Analysts polled by Capital IQ expected a loss of $0.93. The clinical-stage biopharmaceutical company did not report any revenue for the quarter ended Sept. 30. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved